Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINIRINMELT pharmacodynamic and safety study in healthy volunteers
jRCTs041260132Recruiting
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of Nocutil. Primary endpoints: von Willebrand factor ristocetin cofactor activity, von Willebrand factor antigen and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
Nocutil
Beyond the preview
Go deeper on jRCTs041260132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260132.